Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17650217 | 0.88 | GABRA1 (0.37) | GABRA1GABRB2MIF | |
| SCHEMBL17650697 | 0.77 | ABCB11 (0.34) | GABRA1GABRB2MIF | |
| SCHEMBL1964288 | 0.75 | GABRA1 (0.37) | GABRA1GABRB2MIF | |
| SCHEMBL29812934 | 0.75 | GABRA1 (0.46) | GABRA1GABRB2MIF | |
| SCHEMBL158972 | 0.75 | GABRA1 (0.46) | GABRA1GABRB2MIF | |
| SCHEMBL894400 | 0.75 | GABRA1 (0.54) | GABRA1GABRB2MIFP2RY6 | |
| SCHEMBL18827191 | 0.74 | GABRA1 (0.39) | GABRA1GABRB2MIFP2RY6 | |
| SCHEMBL25230727 | 0.72 | ABCB11 (0.32) | — | |
| SCHEMBL17650280 | 0.72 | CYP3A4 (0.32) | GABRA1GABRB2 | |
| SCHEMBL26121064 | 0.72 | CYP1A2 (0.52) | GABRA1GABRB2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2334652-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | GABRA1 1096/4885GABRB2 1276/4885MIF 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.